SG10201906912VA - Glucagon derivatives - Google Patents

Glucagon derivatives

Info

Publication number
SG10201906912VA
SG10201906912VA SG10201906912VA SG10201906912VA SG10201906912VA SG 10201906912V A SG10201906912V A SG 10201906912VA SG 10201906912V A SG10201906912V A SG 10201906912VA SG 10201906912V A SG10201906912V A SG 10201906912VA SG 10201906912V A SG10201906912V A SG 10201906912VA
Authority
SG
Singapore
Prior art keywords
glucagon
peptide
present
treating obesity
receptors
Prior art date
Application number
SG10201906912VA
Inventor
Sung Youb Jung
Young Jin Park
Jong Suk Lee
Jae Hyuk Choi
Chang Ki Lim
Se Chang Kwon
Original Assignee
Hanmi Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Pharmaceutical Co Ltd filed Critical Hanmi Pharmaceutical Co Ltd
Publication of SG10201906912VA publication Critical patent/SG10201906912VA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

GLUCAGON DERIVATIVES The present invention relates to a novel peptide of a glucagon derivative and a composition for preventing or treating obesity comprising the peptide as an active ingredient. The glucagon derivative according to the present invention shows a more excellent activating effect with regard to both glucagon-like peptide-1 receptors and glucagon receptors compared to native glucagon, and thus can be widely used as an effective agent for treating obesity. NO FIGURE
SG10201906912VA 2014-12-30 2015-12-30 Glucagon derivatives SG10201906912VA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020140193691A KR102418477B1 (en) 2014-12-30 2014-12-30 Gluagon Derivatives

Publications (1)

Publication Number Publication Date
SG10201906912VA true SG10201906912VA (en) 2019-09-27

Family

ID=56284668

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201705130XA SG11201705130XA (en) 2014-12-30 2015-12-30 Glucagon derivatives
SG10201906912VA SG10201906912VA (en) 2014-12-30 2015-12-30 Glucagon derivatives

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG11201705130XA SG11201705130XA (en) 2014-12-30 2015-12-30 Glucagon derivatives

Country Status (19)

Country Link
US (3) US10513550B2 (en)
EP (1) EP3240802B1 (en)
JP (1) JP6758297B2 (en)
KR (1) KR102418477B1 (en)
CN (1) CN107250155B (en)
AR (1) AR103323A1 (en)
AU (1) AU2015372767B2 (en)
BR (1) BR112017013845A2 (en)
CA (1) CA2972001A1 (en)
EA (1) EA036479B1 (en)
HK (1) HK1246323A1 (en)
IL (1) IL253001B (en)
MX (1) MX2017008715A (en)
PH (1) PH12017501205A1 (en)
SG (2) SG11201705130XA (en)
TW (1) TWI696631B (en)
UA (1) UA122967C2 (en)
WO (1) WO2016108617A1 (en)
ZA (1) ZA201704328B (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3241841A4 (en) * 2014-12-30 2018-10-17 Hanmi Pharm. Co., Ltd. Glucagon derivative having improved stability
PE20240215A1 (en) 2015-06-30 2024-02-16 Hanmi Pharmaceutical Co Ltd GLUCAGON DERIVATIVE AND A COMPOSITION THAT INCLUDES A LONG-ACTING CONJUGATE THEREOF
TWI622596B (en) 2015-10-26 2018-05-01 美國禮來大藥廠 Glucagon receptor agonists
CN108699125B (en) 2015-12-31 2022-10-28 韩美药品株式会社 glucagon/GLP-1/GIP receptor triple agonists
US20240091318A1 (en) 2022-08-18 2024-03-21 Boehringer Ingelheim International Gmbh Combination therapy comprising long acting glp-1/glucagon and npy2 receptor agonists

Family Cites Families (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
CA2249195A1 (en) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
EP1060746A4 (en) 1998-03-06 2002-06-19 Chugai Pharmaceutical Co Ltd Protein-free preparations
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US6677136B2 (en) 2000-05-03 2004-01-13 Amgen Inc. Glucagon antagonists
GB0121709D0 (en) 2001-09-07 2001-10-31 Imp College Innovations Ltd Food inhibition agent
US7217845B2 (en) 2002-11-25 2007-05-15 Sun Bio, Inc. Bifunctional polyethylene glycol derivatives
GB0300571D0 (en) 2003-01-10 2003-02-12 Imp College Innovations Ltd Modification of feeding behaviour
EP1594530A4 (en) 2003-01-22 2006-10-11 Human Genome Sciences Inc Albumin fusion proteins
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US20050176108A1 (en) 2003-03-13 2005-08-11 Young-Min Kim Physiologically active polypeptide conjugate having prolonged in vivo half-life
WO2005035761A1 (en) 2003-10-16 2005-04-21 Compugen Ltd. Splice variants of preproglucagon, glucagon-like peptide-1 and oxyntomodulin
US20090238838A1 (en) 2003-11-13 2009-09-24 Hanmi Pharm. Ind. Co. Ltd. Insulinotropic peptide conjugate using an immunoglobulin fc
US8263084B2 (en) 2003-11-13 2012-09-11 Hanmi Science Co., Ltd Pharmaceutical composition for treating obesity-related disease comprising insulinotropic peptide conjugate
KR101135244B1 (en) 2007-11-29 2012-04-24 한미사이언스 주식회사 A pharmaceutical composition for treating obesity-related disease comprising insulinotropic peptide conjugate
AU2004282984B2 (en) 2003-11-13 2011-07-14 Hanmi Science Co., Ltd. Protein complex using immunoglobulin fragment andmethod for the preparation thereof
KR20070094909A (en) 2004-12-02 2007-09-27 도만티스 리미티드 Bispecific domain ant1bodies targeting serum albumin and glp-1 or pyy
CA2597649A1 (en) 2005-02-11 2006-08-17 Amylin Pharmaceuticals, Inc. Gip analog and hybrid polypeptides with selectable properties
KR100754667B1 (en) 2005-04-08 2007-09-03 한미약품 주식회사 Immunoglobulin Fc fragment modified by non-peptide polymer and pharmaceutical composition comprising the same
GB0511986D0 (en) 2005-06-13 2005-07-20 Imp College Innovations Ltd Novel compounds and their effects on feeding behaviour
ES2385093T3 (en) 2005-06-13 2012-07-18 Imperial Innovations Limited Oxintomodulin analogues and their effects on eating behavior
CA2617649A1 (en) 2005-08-11 2007-02-22 Amylin Pharmaceuticals, Inc. Hybrid polypeptides with selectable properties
US20090297496A1 (en) 2005-09-08 2009-12-03 Childrens Hospital Medical Center Lysosomal Acid Lipase Therapy for NAFLD and Related Diseases
CA2638800A1 (en) 2006-02-22 2007-09-07 Merck & Co., Inc. Oxyntomodulin derivatives
EP2474318A1 (en) 2006-06-07 2012-07-11 Human Genome Sciences, Inc. Albumin fusion proteins
KR100880509B1 (en) 2006-10-16 2009-01-28 한미약품 주식회사 A Novel vector and expression cell line for mass production of recombinant protein and a process of producing recombinant protein using same
GB0624868D0 (en) 2006-12-13 2007-01-24 Imp Innovations Ltd Novel compounds and their effects on feeding behaviour
TWI428346B (en) 2006-12-13 2014-03-01 Imp Innovations Ltd Novel compounds and their effects on feeding behaviour
JP2008169195A (en) 2007-01-05 2008-07-24 Hanmi Pharmaceutical Co Ltd Insulinotopic peptide drug combo using carrier material
US20090098130A1 (en) * 2007-01-05 2009-04-16 Bradshaw Curt W Glucagon-like protein-1 receptor (glp-1r) agonist compounds
CN101790538B (en) 2007-02-15 2014-07-30 印第安纳大学研究与科技公司 Ucagon/glp-1 receptor co-agonists
DE602008005155D1 (en) 2007-07-10 2011-04-07 Lilly Co Eli GLP-1-FC FUSION PROTEIN FORMULATION
KR101545181B1 (en) 2007-07-27 2015-08-21 바이엘 크롭사이언스 아게 Ternary active compound combinations
EP2187525B1 (en) 2007-08-07 2014-03-12 Fujitsu Limited Error detection device, and error correction/error detection decoding device and method
WO2009046859A2 (en) 2007-09-11 2009-04-16 Mondobiotech Laboratories Ag Use of af12198 and dago as therapeutic agents
JP5771005B2 (en) 2007-10-30 2015-08-26 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ Glucagon antagonist and compound showing GLP-1 agonist activity
US20090181037A1 (en) 2007-11-02 2009-07-16 George Heavner Semi-Synthetic GLP-1 Peptide-FC Fusion Constructs, Methods and Uses
EP2249853A4 (en) 2008-01-30 2012-12-26 Univ Indiana Res & Tech Corp Ester-based peptide prodrugs
EP2300037B1 (en) * 2008-06-17 2016-03-30 Indiana University Research and Technology Corporation Glucagon/glp-1 receptor co-agonists
CN104447980A (en) 2008-06-17 2015-03-25 印第安纳大学研究及科技有限公司 Glucagon analogs exhibiting enhanced solubility and stability in physiological pH buffers
WO2010013012A2 (en) 2008-08-01 2010-02-04 Lund University Bioscience Ab Novel polypeptides and uses thereof
AU2009292643B2 (en) 2008-09-19 2016-02-18 Nektar Therapeutics Polymer conjugates of therapeutic peptides
EP2344200A2 (en) 2008-09-19 2011-07-20 Nektar Therapeutics Modified therapeutics peptides, methods of their preparation and use
FR2936441B1 (en) 2008-09-26 2012-12-07 Rhodia Operations COMPOSITE POLYAMIDE ARTICLE
CN102282166B (en) * 2008-12-15 2015-04-01 西兰制药公司 Glucagon analogues
RU2550696C2 (en) 2008-12-19 2015-05-10 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Amide-based prodrugs of glucagon superfamily peptides
WO2010091122A1 (en) 2009-02-03 2010-08-12 Amunix, Inc. Extended recombinant polypeptides and compositions comprising same
WO2010096052A1 (en) 2009-02-19 2010-08-26 Merck Sharp & Dohme Corp. Oxyntomodulin analogs
WO2010108153A2 (en) 2009-03-20 2010-09-23 Amgen Inc. Carrier immunoglobulins and uses thereof
RU2495881C2 (en) 2009-03-20 2013-10-20 Ханми Холдингс Ко., Лтд. Method of controlling conditions for site-specific binding of polypeptide and non-peptide polymer
SG176858A1 (en) 2009-06-16 2012-02-28 Univ Indiana Res & Tech Corp Gip receptor-active glucagon compounds
UA104766C2 (en) 2009-07-13 2014-03-11 Зіленд Фарма А/С Acylated glucagon analogues
EP2496249B1 (en) 2009-11-03 2016-03-09 Amylin Pharmaceuticals, LLC Glp-1 receptor agonist for use in treating obstructive sleep apnea
WO2011071957A1 (en) 2009-12-07 2011-06-16 Sea Lane Biotechnologies, Llc Conjugates comprising an antibody surrogate scaffold with improved pharmacokinetic properties
WO2011075393A2 (en) 2009-12-18 2011-06-23 Indiana University Research And Technology Corporation Glucagon/glp-1 receptor co-agonists
AR079345A1 (en) 2009-12-22 2012-01-18 Lilly Co Eli OXINTOMODULINE PEPTIDAL ANALOG
AR079344A1 (en) 2009-12-22 2012-01-18 Lilly Co Eli PEPTIDAL ANALOG OF OXINTOMODULIN, PHARMACEUTICAL COMPOSITION THAT UNDERSTANDS AND USES TO PREPARE A USEFUL MEDICINAL PRODUCT TO TREAT NON-INSULINED INDEPENDENT DIABETES AND / OR OBESITY
WO2011088837A1 (en) * 2010-01-20 2011-07-28 Zealand Pharma A/S Treatment of cardiac conditions
US8551946B2 (en) 2010-01-27 2013-10-08 Indiana University Research And Technology Corporation Glucagon antagonist-GIP agonist conjugates and compositions for the treatment of metabolic disorders and obesity
CA2792663A1 (en) * 2010-03-26 2011-09-29 Novo Nordisk A/S Novel glucagon analogues
AR081066A1 (en) 2010-04-02 2012-06-06 Hanmi Holdings Co Ltd INSULIN CONJUGATE WHERE AN IMMUNOGLOBULIN FRAGMENT IS USED
CN103179976A (en) 2010-05-13 2013-06-26 印第安纳大学研究及科技有限公司 Glucagon superfamily peptides exhibiting g protein-coupled receptor activity
CA2796894A1 (en) 2010-06-24 2011-12-29 Indiana University Research And Technology Corporation Amide based glucagon superfamily peptide prodrugs
KR101337797B1 (en) 2010-07-14 2013-12-06 한미사이언스 주식회사 A liquid formulation of long acting human growth hormone conjugate
KR101382593B1 (en) 2010-07-21 2014-04-10 한미사이언스 주식회사 Novel long-acting glucagon conjugate and pharmaceutical composition comprising the same for the prevention and treatment of obesity
KR101383976B1 (en) 2010-09-06 2014-04-10 파나소닉 주식회사 Display device and method of controlling same
CN101974077A (en) 2010-09-15 2011-02-16 南京瑞年天平医药科技有限公司 Novel polypeptide compound
KR101767570B1 (en) 2010-10-26 2017-08-14 한미사이언스 주식회사 A long-lasting conjugate of An anti-obesity peptide derivative complex
KR101303388B1 (en) 2010-10-26 2013-09-03 한미사이언스 주식회사 Liquid formulations of long acting interferon alpha conjugate
CN102010473A (en) 2010-11-10 2011-04-13 曹鹏 Recombinant oxyntomodulin (OXM) fusion protein, and preparation and application thereof
MX2013007327A (en) 2010-12-22 2014-01-08 Marcadia Biotech Inc Methods for treating metabolic disorders and obesity with gip and glp-1 receptor-active glucagon-based peptides.
JP6118500B2 (en) 2011-02-28 2017-04-19 ローム アンド ハース エレクトロニック マテリアルズ エルエルシーＲｏｈｍ ａｎｄ Ｈａａｓ Ｅｌｅｃｔｒｏｎｉｃ Ｍａｔｅｒｉａｌｓ ＬＬＣ Photoresist composition and method for forming photolithography pattern
KR101161526B1 (en) 2011-05-16 2012-07-02 숭실대학교산학협력단 Catalyst electrode of core/shell nanostructure supports and method of it for fuel cell
DK2718318T3 (en) * 2011-06-10 2018-11-05 Hanmi Science Co Ltd New oxyntomodulin derivatives and pharmaceutical compositions for the treatment of obesity comprising these
ES2882520T3 (en) 2011-06-17 2021-12-02 Hanmi Science Co Ltd A conjugate comprising oxyntomodulin and an immunoglobulin fragment and their use
JP6184404B2 (en) 2011-06-22 2017-08-23 インディアナ ユニヴァーシティ リサーチ アンド テクノロジー コーポレイション Glucagon / GLP-1 receptor co-agonist
KR101665009B1 (en) 2012-03-09 2016-10-11 한미사이언스 주식회사 Pharmaceutical composition for the prevention or treatment of non-alcoholic fatty liver disease
BR112014025951A2 (en) 2012-04-19 2017-07-11 Opko Biologics Ltd long-acting oxyntomodulin variants and production methods
TWI599575B (en) * 2012-06-21 2017-09-21 印第安納大學科技研究公司 Glucagon analogs exhibiting gip receptor activity
KR101373563B1 (en) 2012-07-25 2014-03-12 전북대학교산학협력단 Method of derivation for hemodynamics and MR-signal intensity gradient(or shear rate) using Time-Of-Flight - Magnetic Resonance Angiography
KR101968344B1 (en) 2012-07-25 2019-04-12 한미약품 주식회사 A composition for treating hyperlipidemia comprising oxyntomodulin analog
WO2014049610A2 (en) 2012-09-26 2014-04-03 Cadila Healthcare Limited Peptides as gip, glp-1 and glucagon receptors triple-agonist
KR101993393B1 (en) 2012-11-06 2019-10-01 한미약품 주식회사 A composition for treating diabetes or diabesity comprising oxyntomodulin analog
UA126651C2 (en) 2012-11-06 2023-01-11 Ханмі Фарм. Ко., Лтд. LIQUID PROTEIN CONJUGATE COMPOSITION CONTAINING OXYNTHOMODULIN AND AN IMMUNOGLOBULIN FRAGMENT
JP6594856B2 (en) * 2013-04-18 2019-10-23 ノヴォ ノルディスク アー／エス Stable prolonged GLP-1 / glucagon receptor co-agonist for medical use
JP6137046B2 (en) 2014-05-09 2017-05-31 信越化学工業株式会社 Monomer, polymer compound, resist material and pattern forming method
TWI802396B (en) 2014-09-16 2023-05-11 南韓商韓美藥品股份有限公司 Use of a long acting glp-1/glucagon receptor dual agonist for the treatment of non-alcoholic fatty liver disease
WO2019171352A2 (en) 2018-03-08 2019-09-12 Janssen Pharmaceutica Nv Methods of treating severe non-diabetic obesity

Also Published As

Publication number Publication date
CN107250155A (en) 2017-10-13
EP3240802A1 (en) 2017-11-08
KR102418477B1 (en) 2022-07-08
WO2016108617A1 (en) 2016-07-07
US20220025012A1 (en) 2022-01-27
CA2972001A1 (en) 2016-07-07
JP2018505153A (en) 2018-02-22
US20200140515A1 (en) 2020-05-07
AU2015372767A1 (en) 2017-07-13
CN107250155B (en) 2021-08-10
US11254724B2 (en) 2022-02-22
US12018060B2 (en) 2024-06-25
UA122967C2 (en) 2021-01-27
EA036479B1 (en) 2020-11-16
US10513550B2 (en) 2019-12-24
MX2017008715A (en) 2017-11-17
PH12017501205A1 (en) 2017-10-18
EP3240802A4 (en) 2018-10-10
EA201791498A1 (en) 2017-10-31
IL253001B (en) 2022-04-01
ZA201704328B (en) 2021-01-27
BR112017013845A2 (en) 2018-01-02
EP3240802B1 (en) 2021-07-21
TWI696631B (en) 2020-06-21
AU2015372767B2 (en) 2020-07-16
SG11201705130XA (en) 2017-07-28
US20180002395A1 (en) 2018-01-04
TW201632546A (en) 2016-09-16
IL253001A0 (en) 2017-08-31
HK1246323A1 (en) 2018-09-07
JP6758297B2 (en) 2020-09-23
AR103323A1 (en) 2017-05-03
KR20160082026A (en) 2016-07-08

Similar Documents

Publication Publication Date Title
PH12017501205A1 (en) Glucagon derivatives
PH12017502393A1 (en) Glucagon derivative and a composition comprising a long acting conjugate of the same
PH12018502742A1 (en) Glucagon derivative, conjugate thereof, composition comprising same and therapeutic use thereof
TN2018000228A1 (en) Triple activator activating glucagon, glp-1 and gip receptor
ZA202007143B (en) Pyridone derivative, composition thereof and application thereof as anti-influenza drug
IL272232A (en) Glp-1 compositions and uses thereof
TW201613633A (en) Exendin-4 derivatives as selective glucagon receptor agonists
UA118558C2 (en) Peptide compound
MX2016016593A (en) Novel aminoalkyl benzothiazepine derivative and use thereof.
MX2018015657A (en) Heterocyclic compounds as antibacte rials.
GT201700150A (en) GLUCAGON DERIVATIVES WITH IMPROVED STABILITY
PH12017501084A1 (en) Insulin glargine/lixisenatide fixed ratio formulation
PH12018502274A1 (en) Semaglutide in cardiovascular conditions
MX2020003217A (en) Long-acting co-agonists of the glucagon and glp-1 receptors.
MX2017005249A (en) Compounds for use in anthelminthic treatment.
MX2019012285A (en) Methods of treating developmental encephalopathies.
PH12021550122A1 (en) Solubilized apyrases, methods and use
MX2017001047A (en) Compounds for use in anthelminthic treatment.
MX2017008983A (en) Sulfonamide pharmaceutical composition.
PH12018500118A1 (en) Antitussive compositions and methods
MX2018011512A (en) Use of insulin for promoting gastric emptying.
CR20190161A (en) Glucagon derivative, conjugate thereof, composition comprising same and therapeutic use thereof
AR107282A1 (en) TRIPLE AGONIST THAT HAS ACTIVITY FOR A GLUCAGON RECEIVER, A GLUCAGON PEPTIDE 1 RECEIVER (GLP-1) AND A GLUCOSE DEPENDENT INSULINOTROPIC PEPTIDE RECEPTOR (GIP)
IN2014MU00667A (en)
UA93017U (en) "nanovulin-bpx" medication